glp-1 cv outcome trials Cardiovascular and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular outcomes trials: a paradigm
Description
Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts
As GEN s StockWatch reported in September, data from that and two other Phase III studies had analysts projecting $10 billion or more in annual sales, with some of the analysts trimming their estimates after data from orfogliprons second Phase III trial was positive but fell short of market expectations
doi:10.1210/en.143.8.3152
The obesity segment held the largest market share in 2025
Do GLP-1 injections make you tired
